Coya Therapeutics (COYA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
13 May, 2026Executive summary
Annual meeting scheduled for June 25, 2026, to be held virtually at 12:00 p.m. C.T.
Proxy materials and annual report for the year ended December 31, 2025, are available online for review and voting.
Shareholders are encouraged to review all proxy materials before voting and can opt for electronic delivery to support environmental initiatives.
Voting matters and shareholder proposals
Election of two directors: Wilbur Ross and Dieter Weinand, with board recommending a vote FOR both.
Ratification of Weaver and Tidwell, L.L.P. as independent registered public accounting firm for the year ending December 31, 2026, recommended by the board.
Board of directors and corporate governance
Board of Directors has provided recommendations for all voting items, supporting all nominees and auditor ratification.
Latest events from Coya Therapeutics
- Virtual meeting to elect directors and ratify auditor, with strong governance and compensation policies.COYA
Proxy filing13 May 2026 - Q1 2026 saw FDA Fast Track, narrowed net loss, and $50.7M cash runway into H2 2027.COYA
Q1 202612 May 2026 - Treg-focused combination therapies show promise in neurodegeneration with pivotal trials underway.COYA
Investor presentation12 May 2026 - Treg-focused combination therapies show promise in neurodegeneration, with pivotal trials underway.COYA
Corporate presentation1 May 2026 - Treg-focused therapies show promise in neurodegeneration, with pivotal trials underway.COYA
Investor presentation2 Apr 2026 - Resale registration for 2.5M shares from a private placement; no proceeds to the company.COYA
Registration Filing16 Mar 2026 - Clinical progress and financing extended cash runway into 2H 2027 despite higher net loss.COYA
Q4 202516 Mar 2026 - Treg-based therapies advance in neurodegeneration with promising data and major milestones ahead.COYA
Status update5 Mar 2026 - Lead asset advanced, promising FTD data, and major licensing deal set stage for 2026 growth.COYA
Evercore ISI 8th Annual HealthCONx Conference3 Feb 2026